Literature DB >> 31604100

Hidradenitis suppurativa: Current and emerging treatments.

Samantha R Goldburg1, Bruce E Strober2, Michael J Payette3.   

Abstract

The treatment of hidradenitis suppurativa (HS) has remained challenging because of the many knowledge gaps regarding etiology. However, recent studies into the pathogenesis of HS have enabled the investigation of newer therapies. The second article in this continuing medical education series reviews the evidence for established therapies for HS, including anti-inflammatories, antibiotics, and surgery. New and emerging therapies that specifically target cytokines involved in HS pathogenesis will be covered. The potential therapeutic roles of anticytokine therapies, including both the expanded application of existing molecules as well as the specific development of novel therapies for HS are discussed. With increased attention on HS and with numerous clinical trials currently underway, we hope that the variety of treatment options for HS will be expanded.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adalimumab; antibiotics; hidradenitis; secukinumab; ustekinumab

Year:  2019        PMID: 31604100     DOI: 10.1016/j.jaad.2019.08.089

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.

Authors:  Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger
Journal:  Br J Dermatol       Date:  2022-06-02       Impact factor: 11.113

Review 2.  Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil.

Authors:  Maria Cecilia Rivitti-Machado; Renata Ferreira Magalhães; Roberto Souto da Silva; Gleison V Duarte; Fabiana Zs Bosnich; Roberto Gaspar Tunala; Francisco José Forestiero
Journal:  Drugs Context       Date:  2022-01-19

3.  Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management.

Authors:  Stella X Chen; Christina G Lopez; Bina Kassamali; Marlise R Luskin; Alexandra Charrow
Journal:  JAAD Case Rep       Date:  2021-11-24

Review 4.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.

Authors:  Angelo Ruggiero; Fabrizio Martora; Vincenzo Picone; Laura Marano; Gabriella Fabbrocini; Claudio Marasca
Journal:  Biomedicines       Date:  2022-02-16

Review 5.  Colchicine in Managing Skin Conditions: A Systematic Review.

Authors:  Stefano Dastoli; Steven Paul Nisticò; Pietro Morrone; Cataldo Patruno; Antonio Leo; Rita Citraro; Luca Gallelli; Emilio Russo; Giovambattista De Sarro; Luigi Bennardo
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

Review 6.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 7.  Outcomes and Reliability of Perforator Flaps in the Reconstruction of Hidradenitis Suppurativa Defects: A Systemic Review and Meta-Analysis.

Authors:  Camille Vaillant; Yanis Berkane; Elise Lupon; Michael Atlan; Pascal Rousseau; Alexandre G Lellouch; Jérôme Duisit; Nicolas Bertheuil
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

8.  Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation.

Authors:  Ana Luísa João; Nélia Cunha; Joana Cabete
Journal:  Skin Appendage Disord       Date:  2021-03-22

9.  Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.

Authors:  Giulia Rozzo; Alice Ramondetta; Maria Teresa Fierro; Paolo Dapavo; Simone Ribero
Journal:  Dermatol Ther       Date:  2020-06-18       Impact factor: 3.858

10.  Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study.

Authors:  Damon Willems; Mickael Hiligsmann; Hessel H van der Zee; Christopher J Sayed; Silvia M A A Evers
Journal:  Patient       Date:  2021-08-09       Impact factor: 3.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.